標題: Titlebook: Combination Therapies; Biological Response Allan L. Goldstein,Enrico Garaci Book 1992 Plenum Publishing Corporation 1992 AIDS.gene therapy [打印本頁] 作者: Mottled 時間: 2025-3-21 16:11
書目名稱Combination Therapies影響因子(影響力)
書目名稱Combination Therapies影響因子(影響力)學科排名
書目名稱Combination Therapies網(wǎng)絡公開度
書目名稱Combination Therapies網(wǎng)絡公開度學科排名
書目名稱Combination Therapies被引頻次
書目名稱Combination Therapies被引頻次學科排名
書目名稱Combination Therapies年度引用
書目名稱Combination Therapies年度引用學科排名
書目名稱Combination Therapies讀者反饋
書目名稱Combination Therapies讀者反饋學科排名
作者: Humble 時間: 2025-3-21 22:51
Variables Influencing the Sintering of MgOr developing combination chemotherapy regimens, such as increasing dose intensity and combining drugs that have independent antitumor activity, may not apply to those for combining BRMs and cytotoxic drugs. Thus, the rationale for adding BRMs to chemotherapy may be more complex than for combining chemotherapy drugs.作者: MAG 時間: 2025-3-22 00:52 作者: 控制 時間: 2025-3-22 08:31
https://doi.org/10.1007/978-3-322-87843-4an estimated six to ten million HIV-1 infected individuals worldwide and over 160,000 known cases of AIDS in the United States, it is extremely important and urgent to look for strategies to control the disease by antiviral therapy.作者: headway 時間: 2025-3-22 09:28
Bekannte Eigenschaften des Nickelaluminids,stein’s laboratory looked at cyclooxygenase inhibitors, among other agents, to determine whether they might influence or inhibit thymic peptides. These studies demonstrated that acetyl salicylic acid (aspirin) could enhance immune responses and synergize with thymosins.作者: 統(tǒng)治人類 時間: 2025-3-22 14:21
molecules, termed biological response modifiers (BRMs) , have been sequenced, synthesized and produced in large enough quantities to test in animals and humans resulting in the development of new approaches to the treatment of human disease, in particular, cancers and infectious diseases. Advances i作者: 統(tǒng)治人類 時間: 2025-3-22 18:21 作者: 性上癮 時間: 2025-3-22 22:49
https://doi.org/10.1007/978-1-4615-8999-0h advanced local or distant disease. Approximately two-thirds of the all locally confined renal tumors are found incidentally (1). Surgical extirpation is the cornerstone of therapy of localized RCC. In spite of years of research and many clinical trials, the management of metastatic disease remains undefined.作者: 固執(zhí)點好 時間: 2025-3-23 04:39 作者: FEAS 時間: 2025-3-23 08:07
Combinations of Lymphocyte Activating Agents for Expansion of Tumor Infiltrating Lymphocytes from Reotherapy consisting of infusions of the lymphokine Interleukin-2 (IL-2) or IL-2 combined with Lymphokine Activated Killer (LAK) cells (1, 2). Although some patients responded well to these treatments, the overall rate of anti-tumor responses was relatively low (15–30%) and the therapy was limited by dose-dependent IL-2 toxicity.作者: Heresy 時間: 2025-3-23 12:11
The Role of Combination Biologic Therapy in the Immunotherapeutic Approach to the Treatment of Renalh advanced local or distant disease. Approximately two-thirds of the all locally confined renal tumors are found incidentally (1). Surgical extirpation is the cornerstone of therapy of localized RCC. In spite of years of research and many clinical trials, the management of metastatic disease remains undefined.作者: 細胞膜 時間: 2025-3-23 16:49
Combination Therapies with Cytokines and Anti-Cytokines in Murine Opportunistic Infectionsnding of the mechanisms of resistance, and have also provided new clues to the elucidation of the mechanisms of both resistance and pathology, such that the use of cytokines or anti-cytokines appears to be extremely promising for treatment of conditions associated with microbial infection.作者: 敘述 時間: 2025-3-23 19:56
Use of IL-2 and Lymphocytes Following Bone Marrow Transplantationration of IL-2 with or without reinfusion of .-generated LAK cells [2] represents one possible consolidative treatment modality which, if used after BMT, might exert an anti-tumor effect against the minimal residual disease which is assumed to persist after BMT, and thereby prevent or delay recurrence of the malignancy.作者: 歡呼 時間: 2025-3-23 22:45
Combination of Fluorouracil and Interferon: Mechanisms of Interaction and Clinical Studiesr developing combination chemotherapy regimens, such as increasing dose intensity and combining drugs that have independent antitumor activity, may not apply to those for combining BRMs and cytotoxic drugs. Thus, the rationale for adding BRMs to chemotherapy may be more complex than for combining chemotherapy drugs.作者: 山間窄路 時間: 2025-3-24 05:04
Tumor Immunotherapy with Combined Interleukins Injected Perilymphatically: Experimental and Clinicalnsplanted tumors grow and kill their host. Tumor cells can directly suppress host reactivity by secreting soluble mediators, and actively trigger specific or non-specific suppressor mechanisms that block both natural and adaptive host resistance..作者: GRILL 時間: 2025-3-24 08:17 作者: 音樂會 時間: 2025-3-24 13:14
Aspirin as a Biological Response Modifierstein’s laboratory looked at cyclooxygenase inhibitors, among other agents, to determine whether they might influence or inhibit thymic peptides. These studies demonstrated that acetyl salicylic acid (aspirin) could enhance immune responses and synergize with thymosins.作者: HALO 時間: 2025-3-24 16:31 作者: 揮舞 時間: 2025-3-24 21:17 作者: 租約 時間: 2025-3-25 02:40 作者: Incorporate 時間: 2025-3-25 06:26
IL-2 Based Combination Therapy of Malignant Disease: Summary of the Phase I Experience at the Clevel given with rHuIFNα2a 10 MU/m. IM TIW was 22.0 x 10. BRMP Units (MU)/m. IV TIW. Dose limiting toxicities were CNS, pulmonary and cardiovascular. When given with rHuIFNα2a 10.0 MU/m. TIW, the MTD of infusion rIL-2 was 3.0 MU/m./24 hr x 5 days, weekly x 4. We have also treated pts with RCC and MM in P作者: 文藝 時間: 2025-3-25 09:11
Book 1992s revolve around the nature of these substances in vivo, where many of their actions and the majority of their interactions and synergies remain to be elucidated. For example, as these molecules are thought to exert their effects locally, the systemic administration of lymphokines, cytokines and gro作者: 裁決 時間: 2025-3-25 14:58
use of BRMs revolve around the nature of these substances in vivo, where many of their actions and the majority of their interactions and synergies remain to be elucidated. For example, as these molecules are thought to exert their effects locally, the systemic administration of lymphokines, cytokines and gro978-1-4613-6472-6978-1-4615-3340-5作者: somnambulism 時間: 2025-3-25 15:51
Pore Shrinkage and Ostwald Ripening given with rHuIFNα2a 10 MU/m. IM TIW was 22.0 x 10. BRMP Units (MU)/m. IV TIW. Dose limiting toxicities were CNS, pulmonary and cardiovascular. When given with rHuIFNα2a 10.0 MU/m. TIW, the MTD of infusion rIL-2 was 3.0 MU/m./24 hr x 5 days, weekly x 4. We have also treated pts with RCC and MM in P作者: 軍火 時間: 2025-3-25 21:36
The Potential Role of Immunomodulation in the Treatment of HIV-Infection and Malignant Diseasested in several ways. In both, immunodeficiency is related to a poor prognosis.. Also, AIDS may be considered the most important of the clinical states which predisposed to malignancy and up to 20% of HIV seropositive subjects will eventually get malignant diseases.. This suggests that immunorestorative therapy may be useful in both AIDS and cancer.作者: 時代錯誤 時間: 2025-3-26 00:36
M. Astier,S. J. Teichner,P. Vergnonin tumor therapy, the clinical use of these substances has not produced the expected results. Thus an amount of skepticism has arisen about the therapeutical potentiality of the immunostimulating substances and about the importance of the immune system itself towards neoplasia .作者: 占線 時間: 2025-3-26 04:41 作者: output 時間: 2025-3-26 09:09
Plastic Deformation in Polymerspy [1]. The success of BMT is limited largely by a high relapse rate [1]. Attempts to use additional chemotherapy or radiation to decrease the relapse rate have been hampered by the cross-resistance of the tumor to the various agents and by their shared cumulative side effects. The systemic administ作者: laxative 時間: 2025-3-26 14:34 作者: Solace 時間: 2025-3-26 16:54
Pore Shrinkage and Ostwald Ripeninginical evidence of therapeutic synergy. In a Phase I trial of the combination of doxorubicin (DOX) and rIL-2, myelosuppression prevented dose escalation beyond the MTD of DOX 40 mg/m. IV bolus day 1 and rIL-2 3.0 MU/m./24 hr IV on days 2–5, 9–12, and 16–19. Significant increases in peripheral blood 作者: assail 時間: 2025-3-26 21:51 作者: 專心 時間: 2025-3-27 03:51
Variables Influencing the Sintering of MgOents. Preclinical models have suggested interactions between particular BRMs and cytotoxic agents ranging from antagonistic to synergistic. These conflicting preclinical results reflect variations in cell lines, assays, concentrations, duration of the regimen, and sequence of exposure.. The bases fo作者: Insatiable 時間: 2025-3-27 06:09
Dislocation-Activated Sintering Processess. In preimmunisation experiments in mice, the immune system has proved capable of inhibiting syngeneic tumor growth., while lymphocytes from cancer patients have been shown to react with autologous tumor cells in vitro in proliferation and cytotoxicity assays.. Nevertheless, most spontaneous or tra作者: SMART 時間: 2025-3-27 10:42 作者: 印第安人 時間: 2025-3-27 13:43 作者: overreach 時間: 2025-3-27 20:38 作者: Mosaic 時間: 2025-3-27 22:48
https://doi.org/10.1007/978-3-322-87843-4erstanding the pathogenesis, treatment and prevention of the disease. With the identification of human immunodeficiency virus (HIV) as the etiological agent (1–3), it is now possible to investigate approaches to develop treatments for the disease and vaccines for the prevention of the disease. With 作者: 倔強不能 時間: 2025-3-28 05:22
Bekannte Eigenschaften des Nickelaluminids,s are a family of peptide hormones produced by the thymus and thymus-derived tissues such as T lymphocytes, which modulate differentiation of a variety of T cells providing us with immunity against viruses, mycobacteria, fungi and tumors. About ten years ago, while studying thymosins, Dr. Allan Gold作者: locus-ceruleus 時間: 2025-3-28 08:16 作者: CEDE 時間: 2025-3-28 11:54 作者: Aids209 時間: 2025-3-28 16:30 作者: Aqueous-Humor 時間: 2025-3-28 19:07 作者: 擔心 時間: 2025-3-29 02:12
Dislocations in Ceramic and Metal CrystalsThere is considerable controversy whether the immune system is important in controlling human cancers. We review data regarding leukemia control in recipients of bone marrow transplants. These data indicate that several distinct immune-mediated anti-leukemia mechanisms operate. We consider how these mechanisms might be used to treat human cancers.作者: 孤獨無助 時間: 2025-3-29 06:39
https://doi.org/10.1007/978-1-4899-6367-3Prompted by data from our own experiments on therapy of AIDS, we have taken a fresh look at the problem of analyzing potentiation, synergy, antagonism, enhancement of therapeutic index, and other types of drug interactions (1–3). Initial stages of that inquiry revealed the need for new concepts and new analytical methods that include:作者: antidepressant 時間: 2025-3-29 08:39 作者: 充氣女 時間: 2025-3-29 15:20 作者: 死亡率 時間: 2025-3-29 18:57 作者: scrape 時間: 2025-3-29 20:24
COMBO: New Concepts and Methods for Designing and Analyzing Experiments on Combination TherapyPrompted by data from our own experiments on therapy of AIDS, we have taken a fresh look at the problem of analyzing potentiation, synergy, antagonism, enhancement of therapeutic index, and other types of drug interactions (1–3). Initial stages of that inquiry revealed the need for new concepts and new analytical methods that include:作者: acetylcholine 時間: 2025-3-30 02:16 作者: homocysteine 時間: 2025-3-30 04:44 作者: rectocele 時間: 2025-3-30 09:05
Combination Therapy with Thymic Hormones and Cytokines after Chemotherapy in Cancer Treatmentin tumor therapy, the clinical use of these substances has not produced the expected results. Thus an amount of skepticism has arisen about the therapeutical potentiality of the immunostimulating substances and about the importance of the immune system itself towards neoplasia .作者: prosthesis 時間: 2025-3-30 14:54 作者: –scent 時間: 2025-3-30 20:21 作者: CARE 時間: 2025-3-30 22:21
IL-2 Based Combination Therapy of Malignant Disease: Summary of the Phase I Experience at the Clevelinical evidence of therapeutic synergy. In a Phase I trial of the combination of doxorubicin (DOX) and rIL-2, myelosuppression prevented dose escalation beyond the MTD of DOX 40 mg/m. IV bolus day 1 and rIL-2 3.0 MU/m./24 hr IV on days 2–5, 9–12, and 16–19. Significant increases in peripheral blood 作者: Chandelier 時間: 2025-3-31 03:09 作者: 褪色 時間: 2025-3-31 05:55
Combination of Fluorouracil and Interferon: Mechanisms of Interaction and Clinical Studiesents. Preclinical models have suggested interactions between particular BRMs and cytotoxic agents ranging from antagonistic to synergistic. These conflicting preclinical results reflect variations in cell lines, assays, concentrations, duration of the regimen, and sequence of exposure.. The bases fo
